Cullinan Management (CGEM) just unveiled an announcement.
Cullinan Therapeutics, Inc. has appointed seasoned executive Mary Kay Fenton as its new Chief Financial Officer, with immediate effect. Fenton, with a rich background in the biotech sector including roles at Talaris Therapeutics and Vertex Pharmaceuticals, brings extensive experience to the table. Her compensation package includes a $495,000 annual salary, eligibility for a 40% bonus, and an option grant for 200,000 company shares, vesting over four years. Additionally, her agreement outlines severance benefits and health coverage provisions, along with non-solicitation and non-competition clauses post-employment.
See more data about CGEM stock on TipRanks’ Stock Analysis page.
